| Title | Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. |
| Publication Type | Journal Article |
| Year of Publication | 2007 |
| Authors | Wu, Ann C., David A. Paltiel, Karen M. Kuntz, Scott T. Weiss, and Anne L. Fuhlbrigge |
| Journal | The Journal of allergy and clinical immunology |
| Volume | 120 |
| Issue | 5 |
| Pagination | 1146-52 |
| Date Published | 2007 Nov |
| ISSN | 1097-6825 |
| Keywords | Anti-Allergic Agents, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Asthma, Cost-Benefit Analysis, Humans, Models, Theoretical, Severity of Illness Index |
| Abstract | Omalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition. |
| DOI | 10.1111/j.1524-4733.2010.00763.x |
| Alternate Journal | J. Allergy Clin. Immunol. |
